IceCure Medical (ICCM) announced that after nearly a decade of service with IceCure, CFO Ronen Tsimerman has informed the company of his decision to leave the company to pursue new opportunities. The company has initiated a search for a new CFO and has identified compelling candidates with significant experience commercializing disruptive technologies. Some candidates have recently advanced in the selection process to interviews with IceCure’s Board of Directors. Tsimerman will continue in his role until a successor is appointed, to ensure a smooth transition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical Reports Record 2025 ProSense® Sales Following Landmark FDA Breast Cancer Clearance
- IceCure Medical sees FY25 ProSense sales $3.4M
- IceCure Medical Extends Equity Distribution Agreement with Maxim Group to March 2026
- IceCure Medical Shareholders Approve Amended Articles of Association at January 7 Special Meeting
- IceCure Medical Projects Record Q4 2025 Sales Following FDA Approval of ProSense®